Aligos Therapeutics (NASDAQ:ALGS) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Aligos Therapeutics has received a "Sell (D-)" rating from Weiss Ratings, indicating concerns over the company's stock performance.
• In contrast, HC Wainwright issued a "Buy" rating with a $50.00 price target for Aligos Therapeutics, reflecting differing analyst opinions on the stock.
• The company reported a negative earnings per share (EPS) of ($1.53), beating estimates but still reflecting ongoing financial challenges.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a research report on Friday, September 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $50.00.

Aligos Therapeutics Trading Down 0.1%

Shares of NASDAQ:ALGS traded down $0.01 during mid-day trading on Wednesday, hitting $9.84. 37,473 shares of the company traded hands, compared to its average volume of 153,128. The stock has a market cap of $60.49 million, a P/E ratio of -0.50 and a beta of 2.77. Aligos Therapeutics has a 12-month low of $3.76 and a 12-month high of $46.80. The stock has a 50-day moving average price of $9.52 and a two-hundred day moving average price of $7.73.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.35) by $0.82. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%.The company had revenue of $0.97 million for the quarter, compared to analysts' expectations of $0.43 million. As a group, analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Golden State Wealth Management LLC raised its stake in shares of Aligos Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock valued at $44,000 after purchasing an additional 2,674 shares during the period. XTX Topco Ltd bought a new position in Aligos Therapeutics in the 2nd quarter worth about $100,000. AlphaQuest LLC purchased a new position in shares of Aligos Therapeutics in the 1st quarter worth about $130,000. Geode Capital Management LLC boosted its holdings in shares of Aligos Therapeutics by 21.3% in the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company's stock worth $246,000 after purchasing an additional 5,978 shares in the last quarter. Finally, Readystate Asset Management LP purchased a new position in shares of Aligos Therapeutics in the 1st quarter worth about $375,000. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.